TriSalus Life Sciences Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
TLSI$2.85-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Nine months ended September 30, 2024 and 2023
(unaudited, in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss available to common stockholders | $(19,937) | $(23,724) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 551 | 490 |
| Reduction in the carrying amount of right-of-use assets | 233 | 130 |
| Change in fair value of warrants, tranche and SEPA liability | 2,311 | (660) |
| Change in fair value of Initial OrbiMed Warrants and revenue base redemption liabilities | (790) | — |
| Change in fair value of contingent earnout liability | (12,061) | (19,904) |
| Non-cash interest expense | 377 | — |
| Loss on equity issuance | — | 5,691 |
| Extinguishment of tranche liability | — | (1,520) |
| Stock-based compensation expense | 3,744 | 402 |
| Loss on disposal of fixed assets | 18 | 60 |
| Amortization of debt issuance costs | 434 | — |
| Milestone payments to Dynavax | — | 1,000 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (1,358) | (1,477) |
| Inventory | (1,455) | (158) |
| Prepaid expenses | (2,323) | 1,041 |
| Deposits | 43 | — |
| Operating lease liabilities | (238) | (202) |
| Trade payables and accrued liabilities | (4,685) | (2,570) |
| Net cash used in operating activities | (35,136) | (41,401) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (295) | (216) |
| Milestone payments to Dynavax | — | (1,000) |
| Net cash used in investing activities | (295) | (1,216) |
| Cash flows from financing activities: | ||
| Proceeds from the issuance of preferred stock | — | 9,189 |
| Proceeds from the issuance of common stock | 12,586 | — |
| Proceeds from exercise of preferred stock warrants | — | 9,630 |
| Proceeds from Business Combination | — | 36,854 |
| Offering costs related to Business Combination | — | (1,116) |
| Debt issuance costs | (2,593) | — |
| Proceeds from the issuance of debt | 25,000 | — |
| Payments on finance lease liabilities | (65) | (65) |
| Proceeds from the exercise of stock options for common stock | 14 | 94 |
| Net cash provided by financing activities | 34,942 | 54,586 |
| (Decrease) increase in cash, cash equivalents and restricted cash | (489) | 11,969 |
| Cash, cash equivalents and restricted cash, beginning of period | 12,127 | 9,664 |
| Cash, cash equivalents and restricted cash, end of period | $11,638 | $21,633 |
| Supplemental disclosures of cash flow information: | ||
| Fair value of warrants issued with OrbiMed debt | $325 | $— |
| Fair value of revenue base redemption liability related to OrbiMed debt | $425 | $— |
| Fair value of warrants issued with Series B-2 preferred stock | $— | $14,701 |
|---|---|---|
| Right-of-use assets obtained in exchange for new operating lease liabilities | $464 | $— |
| Transfer of warrant liability to preferred stock upon exercise of warrants | $— | $12,082 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.